MedTrace Logo

Stereotactic Magnetic Resonance Guided Radiation Therapy

NCT04115254 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 397

Last updated 2025-11-13

No results posted yet for this study

Summary

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer.

* The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer.
* Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

Conditions

  • Pancreas Cancer
  • Lung Cancer
  • Renal Cancer
  • Adrenal Metastases
  • Prostate Cancer
  • Liver Metastases
  • Oligoprogressive Nodal Metastases
  • Metachronous Nodal Metastases
  • Synchronous Nodal Metastases
  • Mesothelioma
  • Spine Metastases
  • Brain Metastases
  • Borderline Resectable Pancreatic Carcinoma

Interventions

RADIATION

MR-guided Linac

Radiation will be delivered on an MR-guided Linear Accelerator

Sponsors & Collaborators

Principal Investigators

  • Jonathan Leeman, MD · Brigham and Women's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-22
Primary Completion
2028-06-30
Completion
2028-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04115254 on ClinicalTrials.gov